Mustang Bio, Inc.(MBIO)

Description: Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company is developing its proprietary Chimeric Antigen Receptor (CAR) engineered T cells (CAR -T) technology, which uses the patient’s own T cells to engage and destroy specific tumors. The Company, through its agreement with City of Hope National Medical Center, is using three novel CAR T therapies in the development of cancer treatments, including human epidermal growth factor receptor 2 CAR T technology, CS1-specific CAR T technology, and prostate stem cell antigen CAR T technology.

---

Keywords: Medicine Cancer Biopharmaceutical Immune System Immunotherapy Cancer Treatment Cancer Immunotherapy Gene Therapy Virotherapy T Cell Epidermal Growth Factor Receptor Cancer Cell Chimeric Antigen Receptor Immunotherapy Products Cellectis Cancer Immunotherapy Product

---

Home Page: www.mustangbio.com

MBIO Technical Analysis

377 Plantation Street
Worcester, MA 01605
United States
Phone: 781 652 4500

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)